Skip to content
Head to head

BeiGene vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ONC · VRTX

Updated 6 minutes ago

1-year performance, rebased to 100

ONC +3.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
ONCVRTX
Snapshot
Sector--Biotechnology
Last price390.94515.02
Change today-2.19%-1.08%
1-year return+11.9%+22.0%
Market cap$44.66B$130.58B
52-week range253.95 – 424.73412.27 – 568.67
Valuation
P/E (TTM)49.7433.14
P/E percentile, own 5-yr range78th99th
P/B7.676.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.5315.32
Net profit (TTM)$288.99M$3.88B
Revenue (TTM)$6.61B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+33.8%+11.8%
Gross margin89.4%85.5%
Operating margin17.8%33.1%
Net margin13.9%30.7%
Free cash flow (TTM)$1.43B$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership78.7%96.8%
Insider activity (12mo)13 buy / 35 sell28 buy / 22 sell
Short interest (% of float)1.4%1.9%
Analyst consensus100% buy (12)95% buy / 5% hold (21)
Analyst price target$460 (+18%)$624 (+21%)
StockVane view
StockVane Quant RatingC (53)C (68)
Company
Employees12,0006,400
Founded20101989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.